Document:

Exhibit 4.2

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"),
OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED,
HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS (i) A REGISTRATION
STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS SHALL
HAVE BECOME EFFECTIVE WITH REGARD THERETO, OR (ii) AN EXEMPTION FROM
REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS IS
AVAILABLE IN CONNECTION WITH SUCH OFFER, SALE OR TRANSFER.

AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST
RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS
INVOLVED. SEE THE RISK FACTORS SET FORTH UNDER THAT CERTAIN INVESTMENT AGREEMENT
BY AND BETWEEN THE COMPANY AND HOLDER REFERENCED THEREIN AS EXHIBIT J.

Warrant to Purchase
      "N" shares                                    Warrant Number ____
     ----

                        Warrant to Purchase Common Stock
                                       of
                         Meditech Pharmaceuticals, Inc.

     THIS CERTIFIES that Swartz Private Equity, LLC or any subsequent holder
hereof ("Holder"), has the right to purchase from Meditech Pharmaceuticals,
Inc., a Nevada corporation (the "Company"), up to "N" fully paid and
nonassessable shares, wherein "N" is defined below, of the Company's common
stock, $.001 par value per share ("Common Stock"), subject to adjustment as
provided herein, at a price equal to the Exercise Price as defined in Section 3
below, at any time beginning on the Date of Issuance (defined below) and ending
at 5:00 p.m., New York, New York time the date that is five (5) years after the
Date of Issuance (the "Exercise Period"); provided, that, with respect to each
"Put," as that term is defined in that certain Investment Agreement (the
"Investment Agreement") by and between the initial Holder and Company, dated on
or about June 30, 2000, "N" shall equal ten percent (10%) of the number of
shares of Common Stock purchased by the Holder in that Put.

         Holder  agrees with the Company  that this  Warrant to Purchase  Common
 Stock of the Company (this "Warrant") is issued and all rights hereunder shall
be held subject to all of the  conditions,  limitations and provisions set forth
herein.

     1. Date of Issuance and Term.
        --------------------------

     This Warrant shall be deemed to be issued on _____________, ______ ("Date
of Issuance"). The term of this Warrant is five (5) years from the Date of
Issuance.

                                       1
                                   Exhibit D

<PAGE>

     2. Exercise.
        --------

     (a) Manner of Exercise. During the Exercise Period, this Warrant may be
exercised as to all or any lesser number of full shares of Common Stock covered
hereby (the "Warrant Shares") upon surrender of this Warrant, with the Exercise
Form attached hereto as Exhibit A (the "Exercise Form") duly completed and
executed, together with the full Exercise Price (as defined below) for each
share of Common Stock as to which this Warrant is exercised, at the office of
the Company, Attention: Gerald N. Kern, 10474 North 97th Street; Scottsdale, AZ
85258,Telephone: (480) 614-5324, Facsimile: (480) 614-0560, or at such other
office or agency as the Company may designate in writing, by overnight mail,
with an advance copy of the Exercise Form sent to the Company and its Transfer
Agent by facsimile (such surrender and payment of the Exercise Price hereinafter
called the "Exercise of this Warrant").

     (b) Date of Exercise. The "Date of Exercise" of the Warrant shall be
defined as the date that the advance copy of the completed and executed Exercise
Form is sent by facsimile to the Company, provided that the original Warrant and
Exercise Form are received by the Company as soon as practicable thereafter.
Alternatively, the Date of Exercise shall be defined as the date the original
Exercise Form is received by the Company, if Holder has not sent advance notice
by facsimile. The Company shall not be required to deliver the shares of Common
Stock to the Holder until the requirements of Section 2(a) above are satisfied.

     (c) Cancellation of Warrant. This Warrant shall be canceled upon the
Exercise of this Warrant, and, as soon as practical after the Date of Exercise,
Holder shall be entitled to receive Common Stock for the number of shares
purchased upon such Exercise of this Warrant, and if this Warrant is not
exercised in full, Holder shall be entitled to receive a new Warrant (containing
terms identical to this Warrant) representing any unexercised portion of this
Warrant in addition to such Common Stock.

     (d) Holder of Record. Each person in whose name any Warrant for shares of
Common Stock is issued shall, for all purposes, be deemed to be the Holder of
record of such shares on the Date of Exercise of this Warrant, irrespective of
the date of delivery of the Common Stock purchased upon the Exercise of this
Warrant. Nothing in this Warrant shall be construed as conferring upon Holder
any rights as a stockholder of the Company.

     3. Payment of Warrant Exercise Price.
        ---------------------------------

     The Exercise Price ("Exercise Price"), shall initially equal $Y per share
("Initial Exercise Price"), where "Y" shall equal 110% of the Market Price for
the applicable Put (as both are defined in the Investment Agreement) or, if the
Date of Exercise is more than six (6) months after the Date of Issuance, the
lesser of (i) the Initial Exercise Price or (ii) the "Lowest Reset Price," as
that term is defined below. The Company shall calculate a "Reset Price" on each
six-month anniversary date of the Date of Issuance which shall equal one hundred
and ten percent (110%) of the lowest closing bid price of the Common Stock for
the five (5) trading days ending on such six-month anniversary date of the Date
of Issuance. The "Lowest Reset Price" shall equal the lowest Reset Price

                                       2

<PAGE>

determined on any six-month anniversary date of the Date of Issuance preceding
the Date of Exercise, taking into account, as appropriate, any adjustments made
pursuant to Section 5 hereof. Notwithstanding the above, the Exercise Price is
subject to a floor of fifteen cents ($0.15) ("Floor Price"), which Floor Price
shall be adjusted downward in the event of a Forward Stock Split (as defined
below). In the case of a Reverse Stock Split (as defined below), the Floor Price
shall be adjusted upward to account for such Reverse Stock Split, provided
however that (a) in no event shall the Floor Price ever exceed $1.00, and (b)
each time subsequent to a Reverse Stock Split that the Company delivers a "Put
Notice" to Swartz Private Equity, LLC pursuant to the Investment Agreement, and
the Market Price for such Put is less than the Floor Price then in effect, then
the Floor Price shall be reset to equal the Market Price for that Put.
Notwithstanding anything to the contrary herein, the Exercise Price shall be
determined on the Date of Exercise of this Warrant using the value of the Floor
Price in effect at the time of Exercise, and the value of the Floor Price at any
time prior to the Exercise Date shall not affect the calculation of the Reset
Price, Lowest Reset Price or Exercise Price.

     Payment of the Exercise Price may be made by either of the following, or a
combination thereof, at the election of Holder:

     (i) Cash Exercise: cash, bank or cashiers check or wire transfer; or

     (ii) Cashless Exercise: The Holder, at its option, may exercise this
Warrant in a cashless exercise transaction under this subsection (ii) if and
only if, on the Date of Exercise, there is not then in effect a current
registration statement that covers the resale of the shares of Common Stock to
be issued upon exercise of this Warrant. In order to effect a Cashless Exercise,
the Holder shall surrender this Warrant at the principal office of the Company
together with notice of cashless election, in which event the Company shall
issue Holder a number of shares of Common Stock computed using the following
formula:

                                  X = Y (A-B)/A

where: X = the number of shares of Common Stock to be issued to Holder.

       Y = the number of shares of Common Stock for which this Warrant is being
       exercised.

               A = the Market Price of one (1) share of Common Stock (for
               purposes of this Section 3(ii), the "Market Price" shall be
               defined as the average Closing Price of the Common Stock for the
               five (5) trading days prior to the Date of Exercise of this
               Warrant (the "Average Closing Price"), as reported by the O.T.C.
               Bulletin Board, National Association of Securities Dealers
               Automated Quotation System ("Nasdaq") Small Cap Market, or if the
               Common Stock is not traded on the Nasdaq Small Cap Market, the
               Average Closing Price in any other over-the-counter market;
               provided, however, that if the Common Stock is listed on a stock
               exchange, the Market Price shall be the Average Closing Price on
               such exchange for the five (5) trading days prior to the date of
               exercise of the Warrants. If the Common Stock is/was not traded

                                       3

<PAGE>

               during the five (5) trading days prior to the Date of Exercise,
               then the closing price for the last publicly traded day shall be
               deemed to be the closing price for any and all (if applicable)
               days during such five (5) trading day period.

               B = the Exercise Price.

     For purposes hereof, the term "Closing Bid Price" shall mean the closing
bid price on the O.T.C. Bulletin Board, the National Market System ("NMS"), the
New York Stock Exchange, the Nasdaq Small Cap Market, or if no longer traded on
the O.T.C. Bulletin Board, the NMS, the New York Stock Exchange, the Nasdaq
Small Cap Market, the "Closing Bid Price" shall equal the closing price on the
principal national securities exchange or the over-the-counter system on which
the Common Stock is so traded and, if not available, the mean of the high and
low prices on the principal national securities exchange on which the Common
Stock is so traded.

     For purposes of Rule 144 and sub-section (d)(3)(ii) thereof, it is
intended, understood and acknowledged that the Common Stock issuable upon
exercise of this Warrant in a cashless exercise transaction shall be deemed to
have been acquired at the time this Warrant was issued. Moreover, it is
intended, understood and acknowledged that the holding period for the Common
Stock issuable upon exercise of this Warrant in a cashless exercise transaction
shall be deemed to have commenced on the date this Warrant was issued.

     4. Transfer and Registration.
        -------------------------

     (a) Transfer Rights. Subject to the provisions of Section 8 of this
Warrant, this Warrant may be transferred on the books of the Company, in whole
or in part, in person or by attorney, upon surrender of this Warrant properly
completed and endorsed. This Warrant shall be canceled upon such surrender and,
as soon as practicable thereafter, the person to whom such transfer is made
shall be entitled to receive a new Warrant or Warrants as to the portion of this
Warrant transferred, and Holder shall be entitled to receive a new Warrant as to
the portion hereof retained.

     (b) Registrable Securities. The Common Stock issuable upon the exercise of
this Warrant constitutes "Registrable Securities" under that certain
Registration Rights Agreement dated on or about June 30, 2000 between the
Company and certain investors and, accordingly, has the benefit of the
registration rights pursuant to that agreement.

     5. Anti-Dilution Adjustments.
        -------------------------

     (a) Stock Dividend. If the Company shall at any time declare a dividend
payable in shares of Common Stock, then Holder, upon Exercise of this Warrant
after the record date for the determination of holders of Common Stock entitled
to receive such dividend, shall be entitled to receive upon Exercise of this
Warrant, in addition to the number of shares of Common Stock as to which this
Warrant is exercised, such additional shares of Common Stock as such Holder
would have received had this Warrant been exercised immediately prior to such
record date and the Exercise Price will be proportionately adjusted.

                                       4

<PAGE>

     (b) Recapitalization or Reclassification. If the Company shall at any time
effect a recapitalization, reclassification or other similar transaction of such
character that the shares of Common Stock shall be changed into or become
exchangeable for a larger number of shares (a "Forward Stock Split") or smaller
number of shares (a "Reverse Stock Split"), then upon the effective date
thereof, the number of shares of Common Stock which Holder shall be entitled to
purchase upon Exercise of this Warrant shall be increased or decreased, as the
case may be, in direct proportion to the increase or decrease in the number of
shares of Common Stock by reason of such recapitalization, reclassification or
similar transaction, and the Exercise Price shall be, in the case of an increase
in the number of shares, proportionally decreased and, in the case of decrease
in the number of shares, proportionally increased. The Company shall give Holder
the same notice it provides to holders of Common Stock of any transaction
described in this Section 5(b).

     (c) Distributions. If the Company shall at any time distribute for no
consideration to holders of Common Stock cash, evidences of indebtedness or
other securities or assets (other than cash dividends or distributions payable
out of earned surplus or net profits for the current or preceding years) then,
in any such case, Holder shall be entitled to receive, upon Exercise of this
Warrant, with respect to each share of Common Stock issuable upon such exercise,
the amount of cash or evidences of indebtedness or other securities or assets
which Holder would have been entitled to receive with respect to each such share
of Common Stock as a result of the happening of such event had this Warrant been
exercised immediately prior to the record date or other date fixing shareholders
to be affected by such event (the "Determination Date") or, in lieu thereof, if
the Board of Directors of the Company should so determine at the time of such
distribution, a reduced Exercise Price determined by multiplying the Exercise
Price on the Determination Date by a fraction, the numerator of which is the
result of such Exercise Price reduced by the value of such distribution
applicable to one share of Common Stock (such value to be determined by the
Board of Directors of the Company in its discretion) and the denominator of
which is such Exercise Price.

     (d) Notice of Consolidation or Merger. In the event of a merger,
consolidation, exchange of shares, recapitalization, reorganization, or other
similar event, as a result of which shares of Common Stock shall be changed into
the same or a different number of shares of the same or another class or classes
of stock or securities or other assets of the Company or another entity or there
is a sale of all or substantially all the Company's assets (a "Corporate
Change"), then this Warrant shall be exerciseable into such class and type of
securities or other assets as Holder would have received had Holder exercised
this Warrant immediately prior to such Corporate Change; provided, however, that
Company may not affect any Corporate Change unless it first shall have given
thirty (30) days notice to Holder hereof of any Corporate Change.

     (e) Exercise Price Adjusted. As used in this Warrant, the term "Exercise
Price" shall mean the purchase price per share specified in Section 3 of this
Warrant, until the occurrence of an event stated in subsection (a), (b) or (c)
of this Section 5, and thereafter shall mean said price as adjusted from time to
time in accordance with the provisions of said subsection. No such adjustment
under this Section 5 shall be made unless such adjustment would change the
Exercise Price at the time by $.01 or more; provided, however, that all

                                       5

<PAGE>

adjustments not so made shall be deferred and made when the aggregate thereof
would change the Exercise Price at the time by $.01 or more. No adjustment made
pursuant to any provision of this Section 5 shall have the net effect of
increasing the Exercise Price in relation to the split adjusted and distribution
adjusted price of the Common Stock. The number of shares of Common Stock subject
hereto shall increase proportionately with each decrease in the Exercise Price.

     (f) Adjustments: Additional Shares, Securities or Assets. In the event that
at any time, as a result of an adjustment made pursuant to this Section 5,
Holder shall, upon Exercise of this Warrant, become entitled to receive shares
and/or other securities or assets (other than Common Stock) then, wherever
appropriate, all references herein to shares of Common Stock shall be deemed to
refer to and include such shares and/or other securities or assets; and
thereafter the number of such shares and/or other securities or assets shall be
subject to adjustment from time to time in a manner and upon terms as nearly
equivalent as practicable to the provisions of this Section 5.

     6. Fractional Interests.
        --------------------

     No fractional shares or scrip representing fractional shares shall be
issuable upon the Exercise of this Warrant, but on Exercise of this Warrant,
Holder may purchase only a whole number of shares of Common Stock. If, on
Exercise of this Warrant, Holder would be entitled to a fractional share of
Common Stock or a right to acquire a fractional share of Common Stock, such
fractional share shall be disregarded and the number of shares of Common Stock
issuable upon exercise shall be the next higher number of shares.

     7. Reservation of Shares.
        ---------------------

     The Company shall at all times reserve for issuance such number of
authorized and unissued shares of Common Stock (or other securities substituted
therefor as herein above provided) as shall be sufficient for the Exercise of
this Warrant and payment of the Exercise Price. The Company covenants and agrees
that upon the Exercise of this Warrant, all shares of Common Stock issuable upon
such exercise shall be duly and validly issued, fully paid, nonassessable and
not subject to preemptive rights, rights of first refusal or similar rights of
any person or entity.

     8. Restrictions on Transfer.
        ------------------------

     (a) Registration or Exemption Required. This Warrant has been issued in a
transaction exempt from the registration requirements of the Act by virtue of
Regulation D and exempt from state registration under applicable state laws. The
Warrant and the Common Stock issuable upon the Exercise of this Warrant may not
be pledged, transferred, sold or assigned except pursuant to an effective
registration statement or an exemption to the registration requirements of the
Act and applicable state laws.

     (b) Assignment. If Holder can provide the Company with reasonably
satisfactory evidence that the conditions of (a) above regarding registration or
exemption have been satisfied, Holder may sell, transfer, assign, pledge or
otherwise dispose of this Warrant, in whole or in part. Holder shall deliver a

                                       6

<PAGE>

written notice to Company, substantially in the form of the Assignment attached
hereto as Exhibit B, indicating the person or persons to whom the Warrant shall
be assigned and the respective number of warrants to be assigned to each
assignee. The Company shall effect the assignment within ten (10) days, and
shall deliver to the assignee(s) designated by Holder a Warrant or Warrants of
like tenor and terms for the appropriate number of shares.

     9. Benefits of this Warrant.
        ------------------------

     Nothing in this Warrant shall be construed to confer upon any person other
than the Company and Holder any legal or equitable right, remedy or claim under
this Warrant and this Warrant shall be for the sole and exclusive benefit of the
Company and Holder.

     10. Applicable Law.
         --------------

     This Warrant is issued under and shall for all purposes be governed by and
construed in accordance with the laws of the state of Georgia, without giving
effect to conflict of law provisions thereof.

     11. Loss of Warrant.
         ---------------

     Upon receipt by the Company of evidence of the loss, theft, destruction or
mutilation of this Warrant, and (in the case of loss, theft or destruction) of
indemnity or security reasonably satisfactory to the Company, and upon surrender
and cancellation of this Warrant, if mutilated, the Company shall execute and
deliver a new Warrant of like tenor and date.

     12. Notice or Demands.
         -----------------

     Notices or demands pursuant to this Warrant to be given or made by Holder
to or on the Company shall be sufficiently given or made if sent by certified or
registered mail, return receipt requested, postage prepaid, and addressed, until
another address is designated in writing by the Company, to the address set
forth in Section 2(a) above. Notices or demands pursuant to this Warrant to be
given or made by the Company to or on Holder shall be sufficiently given or

                                       7

<PAGE>

made if sent by certified or registered mail, return receipt requested, postage
prepaid, and addressed, to the address of Holder set forth in the Company's
records, until another address is designated in writing by Holder.

     IN WITNESS WHEREOF, the undersigned has executed this Warrant as of the
______ day of _________, 200__.

                                 MEDITECH PHARMACEUTICALS, INC.

                                      By:  /s/  Gerald N. Kern
                                         ---------------------------------------
                                                Gerald N. Kern, Chairman & CEO

                                       8

<PAGE>

                                    EXHIBIT A

                            EXERCISE FORM FOR WARRANT

TO: MEDITECH PHARMACEUTICALS, INC. The undersigned hereby irrevocably exercises
the right to purchase ____________ of the shares of Common Stock (the "Common
Stock") of Meditech Pharmaceuticals, Inc., a Nevada corporation (the "Company"),
evidenced by the attached warrant (the "Warrant"), and herewith makes payment of
the exercise price with respect to such shares in full, all in accordance with
the conditions and provisions of said Warrant.

1. The undersigned agrees not to offer, sell, transfer or otherwise dispose of
any of the Common Stock obtained on exercise of the Warrant, except in
accordance with the provisions of Section 8(a) of the Warrant.

2. The undersigned requests that stock certificates for such shares be issued
free of any restrictive legend, if appropriate, and a warrant representing any
unexercised portion hereof be issued, pursuant to the Warrant in the name of the
undersigned and delivered to the undersigned at the address set forth below:

Dated:

--------------------------------------------------------------------------------
                                    Signature

--------------------------------------------------------------------------------
                                   Print Name

--------------------------------------------------------------------------------
                                     Address

--------------------------------------------------------------------------------

NOTICE

The signature to the foregoing Exercise Form must correspond to the name as
written upon the face of the attached Warrant in every particular, without
alteration or enlargement or any change whatsoever.

--------------------------------------------------------------------------------

                                       9

<PAGE>

                                    EXHIBIT B

                                   ASSIGNMENT

                    (To be executed by the registered holder
                        desiring to transfer the Warrant)

FOR VALUE RECEIVED, the undersigned holder of the attached warrant (the
"Warrant") hereby sells, assigns and transfers unto the person or persons below
named the right to purchase _______ shares of the Common Stock of Meditech
Pharmaceuticals, Inc., evidenced by the attached Warrant and does hereby
irrevocably constitute and appoint _______________________ attorney to transfer
the said Warrant on the books of the Company, with full power of substitution in
the premises.

Dated:_________                                 ______________________________
                                                Signature

Fill in for new registration of Warrant:

-----------------------------------
            Name

-----------------------------------
            Address

-----------------------------------
Please print name and address of assignee
(including zip code number)

--------------------------------------------------------------------------------

NOTICE

The signature to the foregoing Assignment must correspond to the name as written
upon the face of the attached Warrant in every particular, without alteration or
enlargement or any change whatsoever.

--------------------------------------------------------------------------------

                                       10Exhibit 10.1

                               LETTER OF AGREEMENT
                               -------------------

Between Immune Network Research Ltd (IMM) and Meditech Pharmaceuticals Inc.(MPI)

     1.   MPI will grant IMM an irrevocable option to obtain an exclusive
          License to make, have made, promote, sell, and distribute Viraplex and
          MTCH-24, and any derivatives or formulations of Viraplex and MTCH-24,
          under the following terms:

       a)     The region of the license will be worldwide, excluding the United
              States of America.

       b)     The term of the option will be one (1) year from the date of this
              letter of agreement.

       c)     IMM will pay MPI a license fee of US $100,000 upon exercise of the
              option and execution of a superceding license agreement, to be
              negotiated in good faith upon exercise of the option.

       d)     Under a superceding license agreement IMM will pay MPI a royalty
              on net sales of 7% for MTCH-24, or any derivatives or formulations
              of MTCH-24, and 4% for Viraplex, or any derivatives or
              formulations of Viraplex.

     2.   MPI will grant IMM an irrevocable option, for a term of one (1) year,
          to purchase 10 million shares of MPI common stock at an exercise price
          of US$0.03. Effective upon the exercise by IMM of this option, IMM is
          granted two demand reqistration rights, the cost of registration to be
          borne by IMM and unlimited "piggy-back" and S-3 registration rights,
          subject to usual and customary terms and conditions for venture
          capital transactions. A more detailed description of the terms and
          conditions of the registration rights granted hereunder shall be set
          forth in a superceding registration rights agreement to be negotiated
          by the parties no later than the earlier to occur of the execution of
          the snperceding license agreement referenced in section 1(d) or one
          month from the exercise by IMM of the option granted in this section
          2. However, in the event that a superceding registration rights
          agreement is not executed by the parties for any reason, this
          agreement shall be enforceable in accordance with its terms.

     3.   IMM will pay MPI US$25,000 within 2 business days of IMM's receipt
          from the Canadian Venture Exchange of its written acceptance of the
          filing of this agreement.

     4.   IMM will initiate R&D activities on Viraplex and MTCH-24, with
          expenditures of no less than US $20,000, subject to termination under
          paragraph 6. All data from IMM's R&D activities will be provided to
          MPI.

     5.   MPI will provide any pre-clinical and clinical data in their
          possession or under their control for Viraplex and MTCH-24.

     6.   IMM may terminate this agreement at any time, in which case IMM will
          not retain any rights on the intellectual property of the MPI.

     7.   This agreement is subject to regulatory approval for IMM and Board
          approval for both parties.

     8.   The parties will issue a joint announcement of this agreement.

     9.   MPI will, promptly upon execution of this agreement, nominate IMM's
          president to MPI's hoard of
              directors.

IN WITNESS of their understanding, agreement and consent, the parties have
signed this binding agreement Arizona as of the 3 day of February, 2000.

By:  /s/  Gerald N. Kern                  By:  /s/  Dr. Allen Bain
--------------------------------------------------------------------------------
          Gerald N. Kern                            Dr. Allen Bain
          President &CEO                            President
          MEDITECH PHARMACEUTICALS, INC.            IMMUNE NETWORK RESEARCH LTD.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]